NEW YORK – GenMark Diagnostics reported after the close of the market on Tuesday a 118 percent increase in second quarter revenues, driven by COVID-19 testing sales.
The Carlsbad, California-based molecular diagnostics firm reported $40.1 million in revenue, up from $18.4 million in Q2 of 2019 and beating the consensus analyst estimate of $32.7 million.
The firm booked ePlex revenues of $35.2 million for the quarter, representing 195 percent growth over the prior-year quarter, with average annuity per analyzer up 74 percent to $188,000.